1. A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor.
- Author
-
Zaemes J, Alzeer A, Villa K, and Atkins M
- Subjects
- Antibodies, Monoclonal, Humanized immunology, Antineoplastic Agents immunology, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 4 immunology, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Cyclin-Dependent Kinase 6 immunology, Humans, Imidazoles immunology, Male, Melanoma immunology, Middle Aged, Oximes immunology, Pyridones immunology, Pyrimidinones immunology, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Imidazoles therapeutic use, Immunotherapy methods, Melanoma drug therapy, Oximes therapeutic use, Pyridones therapeutic use, Pyrimidinones therapeutic use
- Abstract
Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.
- Published
- 2020
- Full Text
- View/download PDF